论文部分内容阅读
[目的]探讨尿激酶联合依达拉奉治疗急性脑梗塞的疗效。[方法]选择发病时间在3～6h内的脑梗塞患者108例,随机分为常规组、尿激酶组和联合用药组,3组同时给予控制脑水肿、改善微循环等治疗,尿激酶组在此基础上应用尿激酶100万U加入生理盐水100ml,30min内滴注完,联合用药组在尿激酶组基础上加用依达拉奉30mg加入生理盐水100ml滴注,对治疗前后患者的神经功能缺损进行评定,测定血清超氧化物歧化酶(SOD)和丙二醛(MDA)的含量以及统计再灌注发生率。[结果]经溶栓治疗的两组神经功能缺损评分明显低于常规组;与尿激酶组相比,联合用药组的SOD水平显著提高,MDA水平和再灌注发生率明显降低。[结论]尿激酶与依达拉奉合用治疗急性脑梗塞疗效显著,可有效防治再灌注的损伤。
[Objective] To investigate the efficacy of urokinase combined with edaravone in the treatment of acute cerebral infarction. [Methods] One hundred and eighty cerebral infarction patients with onset time within 3 ~ 6h were randomly divided into conventional group, urokinase group and combination group. The three groups were given control of cerebral edema and microcirculation, On the basis of uricase 1 million U added saline 100ml, intravenous infusion within 30min, the combination group on the basis of urokinase plus edaravone 30mg saline 100ml infusion, before and after treatment of patients with neurological function The defects were evaluated. The levels of serum superoxide dismutase (SOD) and malondialdehyde (MDA) and the incidence of reperfusion were measured. [Results] The scores of neurological deficit in the two groups after thrombolysis were significantly lower than those in the conventional group. Compared with the urokinase group, the SOD level in the combination group was significantly increased and the MDA level and the incidence of reperfusion were significantly decreased. [Conclusion] The combination of urokinase and edaravone can effectively treat acute cerebral infarction, which can effectively prevent and treat the reperfusion injury.